Reply to M.A. Slavin et al

Affiliations

¹ Randy A. Taplitz, MD, University of California, San Diego, San Diego, CA; Erin B. Kennedy, MHSc, American Society of Clinical Oncology, Alexandria, VA; and Christopher R. Flowers, MD, Emory University, Atlanta, GA.

Comment

Randy A Taplitz et al. J Clin Oncol. 2019.

. 2019 May 1;37(13):1140-1141.

doi: 10.1200/JCO.18.02227. Epub 2019 Mar 7.

¹ Randy A. Taplitz, MD, University of California, San Diego, San Diego, CA; Erin B. Kennedy, MHSc, American Society of Clinical Oncology, Alexandria, VA; and Christopher R. Flowers, MD, Emory University, Atlanta, GA.

No abstract available

Comment on

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Taplitz RA, et al. J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4. J Clin Oncol. 2018. PMID: 30179565
Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression.
Slavin MA, Worth LJ, Seymour JF, Thursky KA. Slavin MA, et al. J Clin Oncol. 2019 May 1;37(13):1139-1140. doi: 10.1200/JCO.18.01474. Epub 2019 Mar 7. J Clin Oncol. 2019. PMID: 30844318 No abstract available.